A phase 2 randomized trial found no overall survival difference for the everolimus/letrozole backbone combined with ribociclib in recurrent endometrial cancer, but it highlighted subgroup signals tied to prior endocrine therapy and CTNNB1 mutations. The findings were reported as potential benefits despite a neutral headline for the overall study population. The study’s design focused on measuring survival outcomes while also exploring how patient characteristics might predict response to the CDK4/6 inhibitor strategy. The report’s key value is the direction of effect in biomarker-defined groups, which can help guide future trial enrichment. For developers, the result supports continued refinement of treatment selection in endometrial cancer rather than broad adoption across all molecular and treatment-history strata.